193 results about "Kidney disease" patented technology

Provided herein are pharmaceutical compositions comprising carotenoids, including liposomes that encapsulate carotenoids including ionizable carotenoids such as trans-crocetin. The provided compositions have uses in treating diseases, disorders and conditions associated with, but not limited to, infection, endotoxemia, inflammation, sepsis, ischemia, hypoxia, shock, stroke, lung injury, wound healing, traumatic injury, reperfusion injury, cardiovascular disease, kidney disease, liver disease, inflammatory disease, metabolic disease, pulmonary disorders, blood related disorders and hyperproliferative diseases such as cancer. Methods of making, delivering, and using the pharmaceutical compositions are also provided.

The present application relates to heterobicyclic compounds having glucagon-like peptide receptor (GLP-1R) agonist activity, processes for their preparation, pharmaceutical compositions comprising them and their use as GLP-1R agonists or for the treatment or prophylaxis of GLP-1R associated diseases or disorders. In particular, the compounds of the present application are useful for body weight management, for lowering blood sugar and / or for the treatment or prevention of diabetes, diabetic complications, obesity, overweight, dyslipidemia, fatty liver diseases (e.g., non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)), metabolic diseases, cardiovascular diseases, nervous system disorders, mental disorders, kidney diseases, etc. , gastrointestinal diseases, autoimmune diseases, inflammatory diseases, lung diseases, hypothalamic-pituitary-gonad axis related diseases or disorders, cancers and the like.

The invention relates to the technical field of medical care informatics, in particular to a nephropathy medication interaction risk screening system which comprises a data acquisition unit, an SOC chip processing and analysis unit, a risk early warning unit and a man-machine interaction and communication unit. Through multi-source data access, dynamic weight scheduling and Kalman filtering fusion correction, accurate and on-demand acquisition of nephropathy core indexes is realized, and real-time intelligent discrimination of personalized medication risks is realized by relying on knowledge base support, adaptive path adjustment and a safe atomization updating mechanism, so that the risk of the nephropathy is accurately determined. Therefore, the problems that traditional system data acquisition lacks specialized pertinence, risk assessment personalization is insufficient, and model updating is lagged are effectively solved, and the accuracy and timeliness of nephropathy medication interaction risk screening are remarkably improved.

The invention provides application of a product of targeted Vasorin protein in preparation of a product for diagnosing or treating kidney diseases with reduced glucose tolerance, and belongs to the technical field of biological medicines. Vasorin is used as a biomarker of the hypoglucose tolerance nephropathy, the level of Vasorin in urine of a patient is absolutely quantified through an ELISA technology, and the Vasorin has great clinical value and practical significance in early discovery and intervention of the hypoglucose tolerance nephropathy. According to the present invention, the gene or the Vasorin protein for controlling the Vasorin expression is adopted as the target spot, and the specific vector is adopted to perform overexpression on the Vasorin protein, such that the lipid droplet deposition and the reactive oxygen species (ROS) overgeneration in the renal tubular epithelial cell can be effectively improved, and the albumin reabsorption ability of the renal tubular can be improved so as to effectively treat the glucose tolerance reduced nephropathy.

The invention relates to the field of medical informatics, and provides a diabetic nephropathy risk prediction method and system based on a protein marker. The method comprises the following steps: detecting the concentration of a protein marker in a plasma sample of a diabetic to obtain plasma protein marker concentration data; performing longitudinal correlation analysis on the protein markers according to the plasma protein marker concentration data to obtain the kidney disease related protein markers; performing feature screening on the kidney disease related protein marker combination to obtain a core protein marker; establishing a nephropathy risk prediction model through the clinical parameters of the diabetic patient and the core protein marker combination; and outputting a nephropathy risk prediction result of the patient to be detected through the nephropathy risk prediction model. The advanced intervention of the diabetic nephropathy is realized, and the prediction accuracy of the diabetic nephropathy is improved.

Certain aspects of the present disclosure provide a monitoring system comprising a continuous analyte sensor configured to penetrate a skin of a patient and generate a sensor current indicative of analyte levels of the patient, and a sensor electronics module coupled to the continuous analyte sensor. The sensor electronics module comprises an analog to digital converter configured to receive the sensor current and convert the sensor current generated by the continuous analyte sensor into digital signals, a processor configured to convert the digital signals to a set of analyte measurements indicative of the analyte levels of the patient, and a Bluetooth antenna configured to transmit the set of analyte measurements wirelessly to a wireless communications device using Bluetooth or BLE communications protocols.

The invention relates to the technical field of image recognition, and discloses an image feature recognition method and system applied to the early stage of kidney diseases. According to the method, the features in the original ultrasonic image are extracted in parallel, and the micro texture change and the macroscopic form information shown in the abnormal area can be captured respectively, so that the limitation of a traditional single-scale feature extraction method in coping with diffusive and weak-saliency image features is overcome; the local texture feature map and the global structure feature map are analyzed, quantization and positioning of weak texture changes are achieved, priori knowledge is converted into objective indexes, pixel-level fusion is carried out on a texture abnormal map and a region importance weight map, and through the knowledge-guided and data-driven deep fusion method, the deep fusion of the texture abnormal map and the region importance weight map is achieved. It is ensured that the finally recognized abnormal area is not only a statistical outlier but also conforms to importance distribution of an image structure, and high-precision automatic recognition of weak and diffuse features in the kidney medical image is facilitated.

Provided are a method and a kit for quantifying L-FABP or oxidized L-FABP in any sample, a method and a kit for testing for kidney diseases on the basis of the quantifying result of L-FABP or oxidized L-FABP in urine of a subject, and a companion diagnostic drug. This method for quantifying liver type fatty acid binding protein includes a step for promoting an antigen-antibody reaction, and quantifying the liver type fatty acid binding protein under a condition in which the measurement sensitivity of oxidized liver type fatty acid binding protein is higher than that of unoxidized liver type fatty acid binding protein.

The present disclosure provides a method and an apparatus for predicting a progression trajectory from acute kidney injury (AKI) to a kidney disease. The method includes the following steps: receiving a first set of features of a particular acute kidney injury (AKI) patient; selecting a second set of features from the first set of features using a preset algorithm; and predicting, using a first machine-learning model, a progression trajectory of a kidney disease of the particular AKI patient based on the second set of features.

The invention relates to a construction method, an evaluation method and application of an inflammatory nephropathy animal model, and relates to the technical field of nephropathy animal model construction. The construction method comprises the steps that a CRIPSR / Cas9 system is adopted to shear a first targeting site on an Smu region of a mouse immune globulin gene, and a second targeting site on an Sgamma2c region of the mouse immune globulin gene is sheared, so that a base sequence between the first targeting site and the second targeting site is knocked out, and the inflammatory nephropathy animal model is obtained. The application comprises an application of the inflammatory nephropathy animal model constructed by the construction method in screening drugs for treating inflammatory nephropathy and an application in researching a molecular mechanism of occurrence and development of inflammatory nephropathy.

The invention discloses a method for constructing a pressed butterfly mycin glycoside gene engineering strain by using glycosyl transferase and application of the pressed butterfly mycin glycoside gene engineering strain. A strong promoter kasOp * is introduced to the upstream of a glucoside transferase gene pie28 of Streptomyces psammoticus SCSIO NS126, the nucleotide sequence of the strong promoter kasOp * is as shown in SEQ ID NO. 1, and the nucleotide sequence of the glucoside transferase pie28 is as shown in SEQ ID NO. 2. The invention also discloses a preparation method of the Streptomyces psammoticus SCSIO NS126, and the preparation method of the Streptomyces psammoticus SCSIO NS126 comprises the following steps of: introducing the strong promoter kasOp * into the upstream of the glucoside transferase gene pie28. The streptomyces gene engineering strain Streptomyces sp. SK-kas28 constructed by the invention can efficiently express the chalcone glycoside, is widely applied to fermentation production of the chalcone glycoside, and is used for research and development of new drugs for treating kidney diseases and the like.

The invention relates to the technical field of health assessment, in particular to a remote monitoring method and system for kidney disease patients. Similarity is obtained according to trend items and season items of adjacent time sequence segments in the sign monitoring time sequence; obtaining a sign monitoring segment according to the similarity of all adjacent time sequence segments; clustering the physical sign monitoring sections of the patient, and obtaining an abnormal disturbance difference value according to the difference characteristics of the residual items corresponding to the physical sign monitoring sections in the physical sign state cluster; obtaining an abnormal characterization value according to the residual item corresponding to the physical sign monitoring section in the physical sign state cluster, the abnormal disturbance difference value and the physical sign monitoring section; and obtaining a comprehensive abnormal index according to the abnormal representation values of all the physical sign state clusters of the patient. According to the body difference characteristics of the patient and other patients in the patient cluster, the abnormal early warning index is obtained by integrating the difference characteristics of the abnormal indexes and the difference characteristics of the sign monitoring time sequence, and early warning is carried out, so that the accuracy of remotely monitoring the state of the patient is improved.

Provided herein are compounds that are useful in treating cancer, metabolic disease, cardiovascular disease, and kidney disease.

This invention discloses the isolation, extraction, and novel application of a neutral, water-soluble polysaccharide from Sophora japonica extract. The invention extracts a water-soluble, neutral polysaccharide with a molecular weight between 20-22 kDa. This invention uses the Sophora japonica extract to treat renal interstitial fibrosis. Multiple studies, including cellular and animal studies, have demonstrated that the traditional Chinese medicine Sophora japonica can inhibit renal interstitial fibrosis, making it a potential drug for clinical application and bringing greater benefits to patients with kidney disease.

The present application relates to the technical field of pharmaceutical analysis, and in particular to a combined analysis method for exploring the effect of Huangkui capsules on improving chronic kidney injury of tacrolimus based on metabolomics and proteomics. The combined analysis method of the present application explores how Huangkui capsules improve the mechanism of chronic kidney injury of tacrolimus from multiple dimensions, which is beneficial to in-depth analysis of the specific effects of Huangkui capsules at the molecular, cellular and tissue levels, reveals the key path and regulation mechanism of kidney protection, and can also provide a scientific basis for optimizing clinical application, further promoting the modernization of traditional Chinese medicine and its wide application in the treatment of kidney disease.

To provide a method for treating a proteinuric kidney disease.SOLUTION: There is provided a method comprising administering a predetermined daily dosage of effective amounts of voclosporin over a projected treatment period of at least 24 weeks. The method further comprises: (a) assessing an estimated Glomerular Filtration Rate (eGFR) of a subject at at least a first time point and a second time point on different days within the treatment period; and (b) (i) when the eGFR of the subject decreases by more than a target % to below a predetermined value between the first and second time points, reducing the daily dosage by units of 7.9 mg BID or discontinuing the administration of voclosporin to the subject; (ii) when the eGFR of the subject decreases by less than the target % between the first and second time points, continuing to administer the same predetermined daily dosage of voclosporin to the subject.SELECTED DRAWING: Figure 1

The utility model discloses an in vitro fixing device for a nephropathy dialysis tube, which comprises an adjusting semi-ring, an adjusting groove is arranged on the adjusting semi-ring, a moving groove is arranged at the side end of the adjusting semi-ring, the adjusting groove is communicated with the moving groove, a fixing piece is connected in the moving groove in a sliding way, a limiting piece is arranged on the fixing piece, and a locking piece is arranged at the side end of the moving groove; a user is allowed to accurately adjust the position of the fixing piece through the adjusting groove and the fixing piece in sliding connection, it is guaranteed that the dialysis tube is kept stable in the using process, the problem of dialysis tube displacement caused by position deviation or movement is solved, the safety and effectiveness of treatment can be improved, and the fixing piece can be fixed through the clamping block and the clamping plate in a matched mode. According to the fixing device for the dialysis tube, the dialysis tube can be effectively prevented from sliding or shifting in the fixing process, the triangular design of the clamping blocks is matched with the cross-shaped design of the clamping plates, it is ensured that the dialysis tube is firmly fixed, accidental movement, caused by external force or internal movement, of the dialysis tube is reduced, and therefore the comfort level of a patient and the stability of dialysis treatment are improved.

The invention discloses an identification kit and an identification system for a pathogenic T cell subset of IgA nephropathy, and belongs to the technical field of nephropathy detection.According to the identification kit, the identification of the pathogenic T cell subset in peripheral blood of the IgA nephropathy is realized by adopting a fluorescent dye labeled antibody combination, and the antibody combination comprises a CD4 fluorescent antibody, a CD103 fluorescent antibody and an ITGB1 fluorescent antibody. The antibody combination designed by the invention can detect a pathogenic T cell subset in peripheral blood of IgA nephropathy, the T cell subset is in negative correlation with a renal function index eGFR, is in positive correlation with severity of E lesion and T lesion in IgA nephropathy kidney pathological injury oxford typing, and can be used as a significant predictive factor for reduction of eGFR and severity of E lesion and T lesion. The method has an important guiding value for real-time monitoring and prognosis prediction of the IgAN, and opens up a new view for clinical management of the IgAN.

Disclosed are compounds according to Formula (I) or (II), and pharmaceutical compositions comprising them. Also disclosed are therapeutic methods, e.g., of treating kidney diseases, using the compounds of Formula (I) or (II).

It forms an object of the present invention a tetravalent antibody construct capable of selectively binding with high affinity to human EPOR, acting as a hEPOR agonist. It forms a further object said antibody for use in the treatment of kidney diseases and anemias.

The present application relates to the technical field of medical information processing, in particular to an abnormal event automatic classification and recording method in a kidney disease follow-up system, comprising collecting kidney function parameters and symptom codes, identifying abnormal sequences, extracting time anchor points and characteristic identifiers, calculating flip frequency and amplitude, constructing a feature vector to evaluate risk and generating event classification records. In the present application, by constructing an abnormal trigger ordered sequence and extracting anchor points to determine composite features, combining symptom flip frequency to construct a persistence intensity coefficient, quantifying disease complexity from the dimensions of time evolution and etiology coupling, using a multi-dimensional feature vector to fuse physiological amplitude and statistical characteristics, obtaining disease risk probability values through weighted calculation, realizing the transition from qualitative classification to quantitative risk grading, solving the false alarm and missed alarm problems caused by single index determination, providing dynamic diagnosis basis containing risk level for clinical, significantly improving the recognition accuracy and intervention timeliness of the hidden deterioration trend in kidney disease follow-up.

The present invention relates to methods of immunoassay for detecting a biomarker which is an MMP-cleaved fragment of collagen type-I and its use in detecting and / or monitoring diseases such as kidney disease and diseases of the cardiovascular system including the heart.

The present application relates to the precise treatment of kidney disease and the detection technology of intestinal micro-ecological biomarkers, in particular to a biomarker for rapidly screening kidney disease patients treated by leflunomide and application thereof.The present application provides a biomarker for rapidly screening kidney disease patients treated by leflunomide, which can accurately identify whether the patient is an IgAN patient after leflunomide treatment, so as to guide the subsequent medication of the IgAN patient.The results of the specific embodiment of the present application prove that the area under the curve is 0.903, the specificity is 0.83, and the sensitivity is 0.86.

The invention provides a composite plant polypeptide composition for reducing blood glucose, repairing cells, resisting oxidation and enhancing immunity as well as a preparation method and application thereof, and belongs to the technical field of biology. The invention provides a composition. Comprising a protein peptide composed of millet protein peptide, soybean protein isolate peptide, whey protein peptide and sea buckthorn protein peptide, dietary fiber composed of chia seed powder and konjaku flour, a probiotic compound composed of bifidobacterium lactis BB-12 and lactobacillus rhamnosus LGG, fructo-oligosaccharide, balsam pear peptide, a cyclocarya paliurus extract, a corn stigma extract, a mulberry leaf extract, a vitamin E extract, a vitamin E extract, a vitamin E extract, a vitamin E extract, a vitamin E extract and a vitamin E extract. The extract mixture is composed of a radix puerariae extract, a rhizoma polygonati polysaccharide extract, a moringa oleifera leaf extract and leech powder, and the vitamin mineral substance mixture is composed of other functional components. The composition provided by the invention is matched with various proteins, dietary fibers, probiotics, prebiotics, plant extracts, vitamins, minerals, other functional components and the like, so that the purpose of effectively and synergistically improving the conditions of diabetes and nephropathy from multiple targets and multiple ways is finally achieved.

The invention provides a preparation process and a use method of a medicinal and edible substance composition. The medicine overcomes the defects that rejection reaction is insufficient when cancer is treated by a stem cell transplantation method and organ lesions cannot be treated simultaneously when cancer is treated by an immune cell method and a vaccine cell method; the oral liquid comprises the following raw materials in parts by weight: 0.1-3.0 parts of cordyceps militaris, 0.1-3.0 parts of fermented cordyceps sinensis powder, 1.0-3.5 parts of pseudo-ginseng, 1.0-2.5 parts of American ginseng, 1.0-1.5 parts of salvia miltiorrhiza powder or ligusticum wallichii, 1.0-3.0 parts of high-quality gastrodia elata and medicinal pure honey which is 0.9-1.3 times of the total weight of the medicinal materials. The preparation method comprises the following steps: mixing prescription raw materials, crushing, adding honey, and preparing honeyed boluses or beverages. The medicine disclosed by the invention is safe, can treat cancers, diabetes mellitus, heart diseases, liver diseases, nephropathy, uremia or entanglement of a plurality of diseases with high curative effect, and enables patients to be young; according to the invention, messy code genes of a patient can be normally edited while the disease is treated.

The present disclosure relates to methods related to the treatment of B-cell responsive autoimmune glomerulopathies.

Methods of treating type 1 diabetes, improving cardiovascular health, delaying renal function decline, reducing the risk of cardiovascular death and reducing the risk of heart failure hospitalization, while minimizing adverse events such as diabetic ketoacidosis and severe hypoglycemia, using sodium-glucose cotransporter 2 (SGLT2) inhibitors are disclosed. In a preferred method, the SGLT2 inhibitor is sofogliflozin. Also disclosed are prescriptions for developing sofogliflozin and methods of administering sofogliflozin.